and hyponatremia (n = 1) at 12 mg/kg. Grade ≤2 fever or infusion-related reactions occurred in 10 patients. Clearance was dose dependent and within 30% of adult value at 12 mg/kg.
pathway and be involved in the development of the tumor neovascular network. Normal pericytes expressing high levels of endosialin have been shown to proliferate in response to PDGF-BB stimulation through phosphorylation of both the PDGF receptor and the mitogenactivated protein extracellular signal-regulated kinase 1/2 resulting in the expression of the transcription factor c-Fos. 1 Conversely, when endosialin expression is knocked down, PDGF-BB-induced pericyte proliferation is blocked. Disruption of human pericyte proliferation via inhibition of endosialin-dependent signal pathway may be a useful strategy to inhibit tumor angiogenesis. Blocking of endosialin may also have antiangiogenic effects via prevention of vascular remodeling leading to decreased tumor blood flow. 3 Endosialin has also been found to be integral to tumor stroma organization. When ontuxizumab binds to human endosialin, it disrupts the interaction between endosialin and its ligands (fibronectin, collagen type I and IV), preventing protein-protein interactions that are critical for tumor stroma organization. 10 In addition, ontuxizumab may have direct inhibitory effects on mesenchymal cells expressing endosialin via antibody-dependent cellular cytotoxicity.
Clinical trials in adults have demonstrated that ontuxizumab (0.0625 to 16 mg/kg) is safe and tolerable when administered on a weekly schedule. 11 The most common adverse events (AE) have included grade 1-2 fatigue, headache, and infusion toxicities. One dose-limiting toxicity (DLT) of grade 3 vomiting was observed in patients who received 16 mg/kg of ontuxizumab. There were nine additional reported serious AE of nausea (n = 2), vomiting (n = 1), diplopia (n = 1), depressed level of consciousness (n = 1), somnolence (n = 1), speech disorder (n = 1), pyrexia (n = 1), and infusion reaction (n = 1) observed in three of the five adults treated at this dose level. The maximum tolerated dose (MTD) was defined as 12 mg/kg.
Based on pharmacokinetics (PK), subsequent clinical trials have evaluated doses of 1-8 mg/kg weekly to determine the optimal biologic dose of ontuxizumab. 12 We conducted this phase 1 dose escalation study to identify the MTD and/or recommended phase 2 dose (RP2D), to assess the safety profile of ontuxizumab, and to preliminarily define the antitumor activity of ontuxizumab in pediatric patients with relapsed or refractory solid tumors.
METHODS

Patient eligibility
Patients >12 months and <22 years of age with recurrent or refractory solid tumors were eligible. Other eligibility criteria included a Karnofsky/Lansky performance score ≥50, recovery from prior therapy, and adequate organ function. Patients with primary central nervous system (CNS) tumors or prior history of metastatic CNS disease were excluded. Additional exclusion criteria included history of clinically significant bleeding risk, major surgical procedures within 28 days of enrollment, or minor surgical procedures within 7 days of enrollment. Patients with grade ≥2 allergic reactions to prior monoclonal antibody were not eligible when the trial opened. This exclusion criterion was eliminated with Amendment 1. This trial was approved by the Institutional Review Boards of all participating sites. All patients or their legal guardians signed a document of informed consent and assent was obtained according to institutional guidelines.
Drug administration
Ontuxizumab was supplied by Morphotek, Inc. (Exton, PA) and administered intravenously once every 7 days (± 2 days). Infusion rates were as follows: 0.03 mg/kg/min (max 2 mg/min) for the first 15 min, 0.07 mg/kg/min (max 5 mg/min) for the next 15 min, and 0.15 mg/kg/min (max 10 mg/min) for the remainder of the infusion.
Patients were pretreated with acetaminophen, diphenhydramine, and 
Study design
The primary objectives of the study were to (1) To achieve these objectives, a rolling six dose-escalation scheme was used. 13 
Adverse events and definitions of DLT
Response
Tumor response was reported using the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). 14 Disease assessment was required after cycles 1, 3, 5, and then after every third cycle. Objective (partial or complete) responses had to be sustained for a minimum of two consecutive imaging evaluations at least 4 weeks apart. Responses and stable disease (≥6 cycles) were confirmed by central radiologist's review. 
Pharmacokinetic studies
Immunogenicity
Blood samples for the assessment of ADA were collected on all patients at baseline, prior to the day 15 infusion in cycle 1 and prior to the day 1 infusion in all subsequent cycles. Serum was isolated and stored at -80 • C until analysis. Detection of ontuxizumabspecific antibodies in serum samples was accomplished using an immunoassay bridging format based on the formation of ontuxizumab ADA complexes detected in a quasi-quantitative manner via ECL assay.
The sensitivity of this method using a surrogate antiontuxizumab IgG antibody as a positive control standard in human serum was 19 ng/ml in undiluted serum. Assay tolerance to residual ontuxizumab determined that low-level ADA was detectable in the presence of up to approximately 25 g/ml of ontuxizumab in human serum.
Biomarker studies
Tissue from original diagnosis, relapse, or subsequent resection or biopsy prior to treatment with ontuxizumab was submitted for evaluation of baseline expression of endosialin and PDGFR . Slides were prepared from formalin-fixed paraffin-embedded tissue and underwent endosialin and PDGFR immunostaining using TEM-1 clone 9G5, lot 33432C and PDGFR clone 28E1 antibodies. 15 In consenting patients, plasma samples for biomarker analysis were collected at the following time points: day 1 (prior to therapy), days 3-4, and day 8 of cycle 1, and prior to day 1 infusion in subsequent cycles.
A sandwich immunoassay using Meso Scale Discovery R ECL platform was used to quantitate the total level of endosialin and PDGFR in plasma. The range of positive controls used for the endosialin and PDGFR assays was 25-14,000 pg/ml and 5-2,500 pg/ml, respectively.
RESULTS
Twenty-seven patients were enrolled and received at least one dose of ontuxizumab between August 2013 and November 2014. Five of these 27 patients were not fully evaluable for toxicity because they did not complete cycle 1 due to progressive disease (PD).
Baseline characteristics of eligible and evaluable patients are shown ( 
Maximum tolerated dose/RP2D determination
Cycle 1 DLTs are summarized in that contained malignant cells. This toxicity was determined not to be attributable to investigational drug. Based on the described toxicities, the 12 mg/kg dose level was determined to be the RP2D.
Additional toxicities
Adverse events related to ontuxizumab are summarized in Table 3 .
Non-DLT, grade ≥3 regimen-related toxicities in cycle 1 were rare with only one grade 3 hypophosphatemia and one grade 3 anemia reported.
The most common hematologic toxicity was anemia (11 events in 38 delivered cycles). The most common nonhematologic toxicities were AST increased (n = 6), headache (n = 6), hyperglycemia (n = 6), nausea (n = 6), vomiting (n = 6), ALT increased (n = 5), fatigue (n = 5), hyponatremia (n = 5), and grade ≤2 fever or infusion-related reactions occurred in 10 patients.
Pharmacokinetics
All 27 patients participated in PK studies. As per protocol, since the MTD was not reached following escalation to 12 mg/kg, ontuxizumab exposure and CL in patients treated in the dose escalation cohort (n = 6) at 12 mg/kg were compared to adult patients treated at this dose level in prior studies. The ontuxizumab CL was 20.0 ± 8.0 ml/hr compared with 22.6±10.1 ml/hr in adults. 16 The 7-day ontuxizumab exposure was 22,150 ± 2,940 g⋅hr/ml compared with 20,200 ± 2,720 g⋅hr/ml in adults. 16 Thus, the mean ontuxizumab CL at 12 mg/kg in this trial was not significantly different than the reported CL in adults, supporting no further dose escalation.
After expansion at the 12 mg/kg dose level, ontuxizumab PK was determined for all 25 patients who completed PK sampling after the first dose, while steady-state PK and accumulation were evaluable for 21 patients with trough samples on days 8, 15, and 22 (Table 4 ).
The ontuxizumab half-life was similar across dose levels with a mean value for all patients of 84.4 ± 16.7 hr. Ontuxizumab CL appeared to decrease as the dose was increased from 4 to 12 mg/kg; however, CL adjusted for body weight was similar across dose levels with a mean value of 0.49 ± 0.18 ml/hr/kg. Ontuxizumab trough concentrations increased 2.2-fold throughout the first cycle of treatment.
Immunogenicity
Baseline and treatment samples for ADA evaluation were available from 24 of the 27 enrolled patients. Two of 24 patients had a positive ADA detected at baseline. Neither of these subjects had detectable ADA following treatment. None of the subjects developed treatmentinduced ADA response after ontuxizumab administration. However, 22 of the 24 patients had at least one sample that contained ontuxizumab serum concentrations that exceeded the drug tolerance limit of the assay. Therefore, it is possible that the presence of some low-level ADA could be masked, preventing definitive assignment of ADA status in these samples. 
Biomarkers
Tissue-based biomarkers
Plasma-based biomarkers
Responses
Twenty-one of the 27 enrolled patients completed cycle 1. 
